This biotech is on the verge of a groundbreaking innovation, but it might not get over the hump. Reason to buy: A potential paradigm shift That's where Recursion Pharmaceuticals comes in. Its AI algorithm is designed to test various clinical compounds against a library of human genes it contains. It helps predict which compounds are the most likely to be effective at treating various illnesses, thereby speeding up the discovery process and reducing the risk that drugs that enter clinical trials will fail so ...